Ambry Genetics Announces Launch of Their CancerArray™ Product and Services Utilizing aCGH Technology

ALISO VIEJO, Calif., Aug. 31, 2011 /PRNewswire/ -- Ambry Genetics today introduces their new CancerArray™ product and services utilizing aCGH technology.  The Ambry CancerArray™ is a high resolution exon-focused 180K array offering genome-wide probe coverage with higher probe density coverage in over 400 known cancer-associated genes. The array enhances the resolution in these functionally important cancer regions.

(Logo:  http://photos.prnewswire.com/prnh/20110307/LA59848LOGO)

"The CancerArray™ is a novel product for oncology-based researchers who want to detect genome-wide copy number variants with enhanced single-gene resolution in cancer associated regions," said Ardy Arianpour, Ambry's Vice President of Business Development. "We expect to see high demand and use of our CancerArray™ due to the increasing amount of translational oncology research being conducted by biotech and pharmaceutical companies and academic research groups."

The Ambry CancerArray™ is a comprehensive high resolution chromosome analysis approach to detect copy number variants without the need and additional cost for independent traditional karyotyping or single gene deletion/duplication analysis. The Ambry CancerArray™ utilizes aCGH technology to cover the entire genome at an average resolution of 20 kb.  The 180K CancerArray™ also offers increased coverage in over 400 known cancer-associated genes to further enhance the resolution in these functionally important regions.

"The enhanced CancerArray™ content is partially based on the Wellcome Trust Sanger Cancer Gene Census," explained Dr. Anja Kammesheidt, Ambry's Chief Scientific Officer. "The Ambry CancerArray™ will not only detect large copy number changes, but simultaneously will identify very small aberrations, near the single-exon level, in the most important cancer genes associated with germline and somatic variations."

The Ambry CancerArray™ is now ready to be ordered and processed for research purposes. For more information on the CancerArray™ and the full line of Ambry's genomic products and services, please visit our website at http://www.ambrygen.com.

About Ambry Genetics

Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory with headquarters in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has established a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and to the advancement of disease research. To learn more about testing and services available through Ambry Genetics, visit www.ambrygen.com.

SOURCE Ambry Genetics